DSE : ADVENT
Advent Pharma Ltd. — Key statistics
Pharmaceutical Preparations · Bangladesh
Last price 13.4 BDT (At close: Oct 28, 2026) · Market cap 1.21B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Technical report: trend, RSI, support and resistance, charts
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.21B |
| Enterprise Value | 1.29B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | Nov 23, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | 93.13M |
| Shares Outstanding | 93.13M |
| Shares Change (YoY) | -0.62% |
| Shares Change (QoQ) | -0.88% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Ratios
| Measure | Value |
|---|
| PE Ratio | 25.05 |
| Forward PE | n/a |
| PS Ratio | 2.64 |
| PB Ratio | 0.78 |
| P/TBV Ratio | 0.78 |
| P/FCF Ratio | 4,806.05 |
| P/OCF Ratio | 28.39 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 26.81 |
| EV / Sales | 2.81 |
| EV / EBITDA | 9.55 |
| EV / EBIT | 17.97 |
| EV / FCF | 5,110.72 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.81 |
| Quick Ratio | 1.27 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.58 |
| Debt / FCF | 308.23 |
| Interest Coverage | 7.56 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 3.13% |
| Return on Assets (ROA) | 2.30% |
| Return on Invested Capital (ROIC) | 3.41% |
| Return on Capital Employed (ROCE) | 4.03% |
| Weighted Average Cost of Capital (WACC) | 6.15% |
| Revenue Per Employee | 1.45M |
| Profits Per Employee | 151,517 |
| Employee Count | 317 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 4.17 |
Taxes
| Measure | Value |
|---|
| Income Tax | 13.98M |
| Effective Tax Rate | 22.55% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.31 |
| 52-Week Price Change | -7.80% |
| 50-Day Moving Average | 13.75 |
| 200-Day Moving Average | 14.23 |
| Relative Strength Index (RSI) | 44.24 |
| Average Volume (20 Days) | 76,340 |
Shortselling
| Measure | Value |
|---|
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Incomestatement
| Measure | Value |
|---|
| Revenue | 458.15M |
| Gross Profit | 139.05M |
| Operating Income | 71.64M |
| Pretax Income | 62.01M |
| Net Income | 48.03M |
| EBITDA | 134.17M |
| EBIT | 71.64M |
| Earnings Per Share (EPS) | 0.52 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 896,831 |
| Total Debt | 77.65M |
| Net Cash | -76.75M |
| Net Cash Per Share | -0.82 |
| Equity (Book Value) | 1.56B |
| Book Value Per Share | 17.69 |
| Working Capital | 163.39M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 42.65M |
| Capital Expenditures | -42.40M |
| Depreciation & Amortization | 62.53M |
| Net Borrowing | 1.38M |
| Free Cash Flow | 251,917 |
| FCF Per Share | 0.00 |
Margins
| Measure | Value |
|---|
| Gross Margin | 30.35% |
| Operating Margin | 15.64% |
| Pretax Margin | 13.54% |
| Profit Margin | 10.48% |
| EBITDA Margin | 29.29% |
| EBIT Margin | 15.64% |
| FCF Margin | 0.05% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | 0.05 |
| Dividend Yield | 0.38% |
| Dividend Growth (YoY) | -70.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 4.29% |
| FCF Payout Ratio | 554.55% |
| Buyback Yield | 0.62% |
| Shareholder Yield | 1.01% |
| Earnings Yield | 3.99% |
| FCF Yield | 0.02% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Feb 28, 2022 |
| Split Type | Forward |
| Split Ratio | 1.02 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.78 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |